These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

8116 related items for PubMed ID: 1846350

  • 1. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II).
    Teicher BA, Holden SA, Herman TS, Sotomayor EA, Khandekar V, Rosbe KW, Brann TW, Korbut TT, Frei E.
    Int J Cancer; 1991 Jan 21; 47(2):252-60. PubMed ID: 1846350
    [Abstract] [Full Text] [Related]

  • 2. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).
    Teicher BA, Holden SA, Kelley MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD, Frei E.
    Cancer Res; 1987 Jan 15; 47(2):388-93. PubMed ID: 3539321
    [Abstract] [Full Text] [Related]

  • 3. Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.
    Brooks SE, Korbut TT, Dupuis NP, Holden SA, Teicher BA.
    Cancer Chemother Pharmacol; 1995 Jan 15; 36(5):431-8. PubMed ID: 7634385
    [Abstract] [Full Text] [Related]

  • 4. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
    Hospers GA, Mulder NH, de Jong B, de Ley L, Uges DR, Fichtinger-Schepman AM, Scheper RJ, de Vries EG.
    Cancer Res; 1988 Dec 01; 48(23):6803-7. PubMed ID: 2846161
    [Abstract] [Full Text] [Related]

  • 5. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
    Twentyman PR, Wright KA, Mistry P, Kelland LR, Murrer BA.
    Cancer Res; 1992 Oct 15; 52(20):5674-80. PubMed ID: 1327513
    [Abstract] [Full Text] [Related]

  • 6. cis-Diamminedichloroplatinum(II) resistant human tumor cell lines are collaterally sensitive to PtCl4(Rh-123)2: evidence for mitochondrial involvement.
    Ara G, Kusumoto T, Korbut TT, Cullere-Luengo F, Teicher BA.
    Cancer Res; 1994 Mar 15; 54(6):1497-502. PubMed ID: 8137254
    [Abstract] [Full Text] [Related]

  • 7. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
    Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG.
    Cancer Res; 1992 Dec 15; 52(24):6885-9. PubMed ID: 1458477
    [Abstract] [Full Text] [Related]

  • 8. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ, Kelland LR, Harrap KR.
    Br J Cancer; 1993 Aug 15; 68(2):240-50. PubMed ID: 8347478
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
    Fukuda M, Ohe Y, Kanzawa F, Oka M, Hara K, Saijo N.
    Anticancer Res; 1995 Aug 15; 15(2):393-8. PubMed ID: 7763011
    [Abstract] [Full Text] [Related]

  • 10. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
    Ohmori T, Morikage T, Sugimoto Y, Fujiwara Y, Kasahara K, Nishio K, Ohta S, Sasaki Y, Takahashi T, Saijo N.
    Jpn J Cancer Res; 1993 Jan 15; 84(1):83-92. PubMed ID: 8383649
    [Abstract] [Full Text] [Related]

  • 11. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA, Herman TS, Holden SA, Epelbaum R, Liu SD, Frei E.
    Cancer Res; 1991 Feb 01; 51(3):780-4. PubMed ID: 1988117
    [Abstract] [Full Text] [Related]

  • 12. A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance.
    Hospers GA, Meijer C, de Leij L, Uges DR, Mulder NH, de Vries EG.
    Int J Cancer; 1990 Jul 15; 46(1):138-44. PubMed ID: 2163989
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)].
    Mellish KJ, Barnard CF, Kelland LR, Harrap KR.
    Int J Cancer; 1994 Oct 01; 59(1):65-70. PubMed ID: 7927906
    [Abstract] [Full Text] [Related]

  • 15. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
    Wang YY, Teicher BA, Shea TC, Holden SA, Rosbe KW, al-Achi A, Henner WD.
    Cancer Res; 1989 Nov 15; 49(22):6185-92. PubMed ID: 2804968
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
    Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR.
    Br J Cancer; 1991 Aug 15; 64(2):215-20. PubMed ID: 1892748
    [Abstract] [Full Text] [Related]

  • 18. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
    Jones M, Siracky J, Kelland LR, Harrap KR.
    Br J Cancer; 1993 Jan 15; 67(1):24-9. PubMed ID: 8427780
    [Abstract] [Full Text] [Related]

  • 19. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
    Perez RP, O'Dwyer PJ, Handel LM, Ozols RF, Hamilton TC.
    Int J Cancer; 1991 May 10; 48(2):265-9. PubMed ID: 2019469
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N, Lam YM, Pym J, Campling BG.
    Cancer; 1996 May 01; 77(9):1797-808. PubMed ID: 8646677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 406.